Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy

Bela R. Turk, Benjamin E. Theisen, Christina L. Nemeth, Joel S. Marx, Xiaohai Shi, Melissa Rosen, Richard O. Jones, Ann B. Moser, Paul A. Watkins, Gerald V. Raymond, Carol Tiffany, Ali Fatemi

Research output: Research - peer-reviewArticle

Abstract

IMPORTANCE X-linked adrenoleukodystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause of which is unknown. Determining differences in antioxidant capacity and superoxide dismutase (SOD) levels between phenotypesmay allow for the generation of a clinical biomarker for predicting the onset of cALD, as well as initiating a more timely lifesaving therapy. OBJECTIVE To identify variations in the levels of antioxidant capacity and SOD activity between ALD phenotypes in patients with cALD or adrenomyeloneuropathy (AMN), heterozygote female carriers, and healthy controls and, in addition, correlate antioxidant levels with clinical outcome scores to determine a possible predictive value. DESIGN, SETTING, AND PARTICIPANTS Samples of monocytes and blood plasmawere prospectively collected from healthy controls, heterozygote female carriers, and patients with AMN or cALD.We are counting each patient as 1 sample in our study. Because adrenoleukodystrophy is an X-linked disease, the affected group populations of cALD and AMN are all male. The heterozygote carriers are all female. The samples were assayed for total antioxidant capacity and SOD activity. The data were collected in an academic hospital setting. Eligibility criteria included patients who received a diagnosis of ALD and heterozygote female carriers, both of which groups were compared with age-matched controls. The prospective samples (n = 30) were collected between January 2015 to January 2016, and existing samples were collected from tissue storage banks at the Kennedy Krieger Institute (n = 30). The analyses were performed during the first 3 months of 2016. MAIN OUTCOME AND MEASURES Commercially available total antioxidant capacity and SOD assays were performed on samples of monocytes and blood plasma and correlated with magnetic resonance imaging severity score. RESULTS A reduction in antioxidant capacity was shown between the healthy controls (0.225 mmol trolox equivalent) and heterozygote carriers (0.181 mmol trolox equivalent), and significant reductions were seen between healthy controls and patients with AMN (0.102 mmol trolox equivalent; P < .01), as well as healthy controls and patients with cALD (0.042 mmol trolox equivalent; P < .01). Superoxide dismutase activity in human blood plasma mirrored these reductions between prospectively collected samples from healthy controls (2.66 units/mg protein) and samples from heterozygote female carriers (1.91 units/mg protein), patients with AMN (1.39 units/mg protein; P = .01), and patients with cALD (0.8 units/mg protein; P < .01). Further analysis of SOD activity in biobank samples showed significant reductions between patients with AMN (0.89 units/mg protein) and patients with cALD (0.18 units/mg protein) (P = .03). Plasma SOD levels from patients with cALD demonstrated an inverse correlation to brain magnetic resonance imaging severity score (R2 = 0.75, P < .002). Longitudinal plasma SOD samples from the same patients (n = 4) showed decreased activity prior to and at the time of cerebral diagnosis over a period of 13 to 42 months (mean period, 24 months). CONCLUSIONS AND RELEVANCE Plasma SOD may serve as a potential biomarker for cerebral disease in ALD following future prospective studies.

LanguageEnglish (US)
Pages519-524
Number of pages6
JournalJAMA Neurology
Volume74
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Adrenoleukodystrophy
Superoxide Dismutase
Antioxidants
Heterozygote
Proteins
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
Monocytes
Biomarkers
Magnetic Resonance Imaging
Phenotype
Tissue Banks
Population Groups
Human Activities
Outcome Assessment (Health Care)
Prospective Studies
Brain
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Turk, B. R., Theisen, B. E., Nemeth, C. L., Marx, J. S., Shi, X., Rosen, M., ... Fatemi, A. (2017). Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. JAMA Neurology, 74(5), 519-524. DOI: 10.1001/jamaneurol.2016.5715

Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. / Turk, Bela R.; Theisen, Benjamin E.; Nemeth, Christina L.; Marx, Joel S.; Shi, Xiaohai; Rosen, Melissa; Jones, Richard O.; Moser, Ann B.; Watkins, Paul A.; Raymond, Gerald V.; Tiffany, Carol; Fatemi, Ali.

In: JAMA Neurology, Vol. 74, No. 5, 01.05.2017, p. 519-524.

Research output: Research - peer-reviewArticle

Turk, BR, Theisen, BE, Nemeth, CL, Marx, JS, Shi, X, Rosen, M, Jones, RO, Moser, AB, Watkins, PA, Raymond, GV, Tiffany, C & Fatemi, A 2017, 'Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy' JAMA Neurology, vol 74, no. 5, pp. 519-524. DOI: 10.1001/jamaneurol.2016.5715
Turk BR, Theisen BE, Nemeth CL, Marx JS, Shi X, Rosen M et al. Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. JAMA Neurology. 2017 May 1;74(5):519-524. Available from, DOI: 10.1001/jamaneurol.2016.5715
Turk, Bela R. ; Theisen, Benjamin E. ; Nemeth, Christina L. ; Marx, Joel S. ; Shi, Xiaohai ; Rosen, Melissa ; Jones, Richard O. ; Moser, Ann B. ; Watkins, Paul A. ; Raymond, Gerald V. ; Tiffany, Carol ; Fatemi, Ali. / Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. In: JAMA Neurology. 2017 ; Vol. 74, No. 5. pp. 519-524
@article{6df7021f5e414ac2a928f57cf9946dae,
title = "Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy",
abstract = "IMPORTANCE X-linked adrenoleukodystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause of which is unknown. Determining differences in antioxidant capacity and superoxide dismutase (SOD) levels between phenotypesmay allow for the generation of a clinical biomarker for predicting the onset of cALD, as well as initiating a more timely lifesaving therapy. OBJECTIVE To identify variations in the levels of antioxidant capacity and SOD activity between ALD phenotypes in patients with cALD or adrenomyeloneuropathy (AMN), heterozygote female carriers, and healthy controls and, in addition, correlate antioxidant levels with clinical outcome scores to determine a possible predictive value. DESIGN, SETTING, AND PARTICIPANTS Samples of monocytes and blood plasmawere prospectively collected from healthy controls, heterozygote female carriers, and patients with AMN or cALD.We are counting each patient as 1 sample in our study. Because adrenoleukodystrophy is an X-linked disease, the affected group populations of cALD and AMN are all male. The heterozygote carriers are all female. The samples were assayed for total antioxidant capacity and SOD activity. The data were collected in an academic hospital setting. Eligibility criteria included patients who received a diagnosis of ALD and heterozygote female carriers, both of which groups were compared with age-matched controls. The prospective samples (n = 30) were collected between January 2015 to January 2016, and existing samples were collected from tissue storage banks at the Kennedy Krieger Institute (n = 30). The analyses were performed during the first 3 months of 2016. MAIN OUTCOME AND MEASURES Commercially available total antioxidant capacity and SOD assays were performed on samples of monocytes and blood plasma and correlated with magnetic resonance imaging severity score. RESULTS A reduction in antioxidant capacity was shown between the healthy controls (0.225 mmol trolox equivalent) and heterozygote carriers (0.181 mmol trolox equivalent), and significant reductions were seen between healthy controls and patients with AMN (0.102 mmol trolox equivalent; P < .01), as well as healthy controls and patients with cALD (0.042 mmol trolox equivalent; P < .01). Superoxide dismutase activity in human blood plasma mirrored these reductions between prospectively collected samples from healthy controls (2.66 units/mg protein) and samples from heterozygote female carriers (1.91 units/mg protein), patients with AMN (1.39 units/mg protein; P = .01), and patients with cALD (0.8 units/mg protein; P < .01). Further analysis of SOD activity in biobank samples showed significant reductions between patients with AMN (0.89 units/mg protein) and patients with cALD (0.18 units/mg protein) (P = .03). Plasma SOD levels from patients with cALD demonstrated an inverse correlation to brain magnetic resonance imaging severity score (R2 = 0.75, P < .002). Longitudinal plasma SOD samples from the same patients (n = 4) showed decreased activity prior to and at the time of cerebral diagnosis over a period of 13 to 42 months (mean period, 24 months). CONCLUSIONS AND RELEVANCE Plasma SOD may serve as a potential biomarker for cerebral disease in ALD following future prospective studies.",
author = "Turk, {Bela R.} and Theisen, {Benjamin E.} and Nemeth, {Christina L.} and Marx, {Joel S.} and Xiaohai Shi and Melissa Rosen and Jones, {Richard O.} and Moser, {Ann B.} and Watkins, {Paul A.} and Raymond, {Gerald V.} and Carol Tiffany and Ali Fatemi",
year = "2017",
month = "5",
doi = "10.1001/jamaneurol.2016.5715",
volume = "74",
pages = "519--524",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy

AU - Turk,Bela R.

AU - Theisen,Benjamin E.

AU - Nemeth,Christina L.

AU - Marx,Joel S.

AU - Shi,Xiaohai

AU - Rosen,Melissa

AU - Jones,Richard O.

AU - Moser,Ann B.

AU - Watkins,Paul A.

AU - Raymond,Gerald V.

AU - Tiffany,Carol

AU - Fatemi,Ali

PY - 2017/5/1

Y1 - 2017/5/1

N2 - IMPORTANCE X-linked adrenoleukodystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause of which is unknown. Determining differences in antioxidant capacity and superoxide dismutase (SOD) levels between phenotypesmay allow for the generation of a clinical biomarker for predicting the onset of cALD, as well as initiating a more timely lifesaving therapy. OBJECTIVE To identify variations in the levels of antioxidant capacity and SOD activity between ALD phenotypes in patients with cALD or adrenomyeloneuropathy (AMN), heterozygote female carriers, and healthy controls and, in addition, correlate antioxidant levels with clinical outcome scores to determine a possible predictive value. DESIGN, SETTING, AND PARTICIPANTS Samples of monocytes and blood plasmawere prospectively collected from healthy controls, heterozygote female carriers, and patients with AMN or cALD.We are counting each patient as 1 sample in our study. Because adrenoleukodystrophy is an X-linked disease, the affected group populations of cALD and AMN are all male. The heterozygote carriers are all female. The samples were assayed for total antioxidant capacity and SOD activity. The data were collected in an academic hospital setting. Eligibility criteria included patients who received a diagnosis of ALD and heterozygote female carriers, both of which groups were compared with age-matched controls. The prospective samples (n = 30) were collected between January 2015 to January 2016, and existing samples were collected from tissue storage banks at the Kennedy Krieger Institute (n = 30). The analyses were performed during the first 3 months of 2016. MAIN OUTCOME AND MEASURES Commercially available total antioxidant capacity and SOD assays were performed on samples of monocytes and blood plasma and correlated with magnetic resonance imaging severity score. RESULTS A reduction in antioxidant capacity was shown between the healthy controls (0.225 mmol trolox equivalent) and heterozygote carriers (0.181 mmol trolox equivalent), and significant reductions were seen between healthy controls and patients with AMN (0.102 mmol trolox equivalent; P < .01), as well as healthy controls and patients with cALD (0.042 mmol trolox equivalent; P < .01). Superoxide dismutase activity in human blood plasma mirrored these reductions between prospectively collected samples from healthy controls (2.66 units/mg protein) and samples from heterozygote female carriers (1.91 units/mg protein), patients with AMN (1.39 units/mg protein; P = .01), and patients with cALD (0.8 units/mg protein; P < .01). Further analysis of SOD activity in biobank samples showed significant reductions between patients with AMN (0.89 units/mg protein) and patients with cALD (0.18 units/mg protein) (P = .03). Plasma SOD levels from patients with cALD demonstrated an inverse correlation to brain magnetic resonance imaging severity score (R2 = 0.75, P < .002). Longitudinal plasma SOD samples from the same patients (n = 4) showed decreased activity prior to and at the time of cerebral diagnosis over a period of 13 to 42 months (mean period, 24 months). CONCLUSIONS AND RELEVANCE Plasma SOD may serve as a potential biomarker for cerebral disease in ALD following future prospective studies.

AB - IMPORTANCE X-linked adrenoleukodystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause of which is unknown. Determining differences in antioxidant capacity and superoxide dismutase (SOD) levels between phenotypesmay allow for the generation of a clinical biomarker for predicting the onset of cALD, as well as initiating a more timely lifesaving therapy. OBJECTIVE To identify variations in the levels of antioxidant capacity and SOD activity between ALD phenotypes in patients with cALD or adrenomyeloneuropathy (AMN), heterozygote female carriers, and healthy controls and, in addition, correlate antioxidant levels with clinical outcome scores to determine a possible predictive value. DESIGN, SETTING, AND PARTICIPANTS Samples of monocytes and blood plasmawere prospectively collected from healthy controls, heterozygote female carriers, and patients with AMN or cALD.We are counting each patient as 1 sample in our study. Because adrenoleukodystrophy is an X-linked disease, the affected group populations of cALD and AMN are all male. The heterozygote carriers are all female. The samples were assayed for total antioxidant capacity and SOD activity. The data were collected in an academic hospital setting. Eligibility criteria included patients who received a diagnosis of ALD and heterozygote female carriers, both of which groups were compared with age-matched controls. The prospective samples (n = 30) were collected between January 2015 to January 2016, and existing samples were collected from tissue storage banks at the Kennedy Krieger Institute (n = 30). The analyses were performed during the first 3 months of 2016. MAIN OUTCOME AND MEASURES Commercially available total antioxidant capacity and SOD assays were performed on samples of monocytes and blood plasma and correlated with magnetic resonance imaging severity score. RESULTS A reduction in antioxidant capacity was shown between the healthy controls (0.225 mmol trolox equivalent) and heterozygote carriers (0.181 mmol trolox equivalent), and significant reductions were seen between healthy controls and patients with AMN (0.102 mmol trolox equivalent; P < .01), as well as healthy controls and patients with cALD (0.042 mmol trolox equivalent; P < .01). Superoxide dismutase activity in human blood plasma mirrored these reductions between prospectively collected samples from healthy controls (2.66 units/mg protein) and samples from heterozygote female carriers (1.91 units/mg protein), patients with AMN (1.39 units/mg protein; P = .01), and patients with cALD (0.8 units/mg protein; P < .01). Further analysis of SOD activity in biobank samples showed significant reductions between patients with AMN (0.89 units/mg protein) and patients with cALD (0.18 units/mg protein) (P = .03). Plasma SOD levels from patients with cALD demonstrated an inverse correlation to brain magnetic resonance imaging severity score (R2 = 0.75, P < .002). Longitudinal plasma SOD samples from the same patients (n = 4) showed decreased activity prior to and at the time of cerebral diagnosis over a period of 13 to 42 months (mean period, 24 months). CONCLUSIONS AND RELEVANCE Plasma SOD may serve as a potential biomarker for cerebral disease in ALD following future prospective studies.

UR - http://www.scopus.com/inward/record.url?scp=85018862279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018862279&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2016.5715

DO - 10.1001/jamaneurol.2016.5715

M3 - Article

VL - 74

SP - 519

EP - 524

JO - JAMA Neurology

T2 - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 5

ER -